Colorectal Cancer Clinical Trial
Official title:
A Phase II Study Assessing Tumor Blood Flow as Measured by Dynamic Contrast Enhanced MRI in Patients With Metastatic Colorectal Cancer Receiving FOLFOX Alone Versus Patients Randomized to Receive FOLFOX Plus Bevacizumab at 5mg/kg or 10mg/kg.
Verified date | April 2020 |
Source | Abramson Cancer Center of the University of Pennsylvania |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor
growth in different ways. Some block the ability of tumor cells to grow and spread. Others
find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab
may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving
bevacizumab together with combination chemotherapy may kill more tumor cells. Diagnostic
procedures, such as MRI, may help doctors predict a patient's response to treatment and help
plan the best treatment.
PURPOSE: This randomized phase II trial is studying how well MRI works in predicting response
to combination chemotherapy given together with bevacizumab in treating patients with
advanced or metastatic colorectal cancer.
Status | Terminated |
Enrollment | 5 |
Est. completion date | October 2009 |
Est. primary completion date | July 2009 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 120 Years |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum - Patients receiving bevacizumab must have tumor tissue available for immunohistochemical analysis - Formalin-fixed, paraffin-embedded tissue from previous biopsy or surgical resection is sufficient - Measurable disease, defined by RECIST as = 1 lesion that can be accurately measured in = 1 dimension (longest diameter to be recorded) as = 20 mm by conventional techniques (i.e., CT or MRI) - CEA elevation alone is insufficient for study entry - No known brain metastases PATIENT CHARACTERISTICS: Criteria for all patients - ECOG performance status 0-1 - Life expectancy > 3 months - Granulocytes = 1,500/mL - Platelet Count = 100,000/mL - Creatinine = 1.5 times upper limit of normal (ULN) - Bilirubin = 1.5 times ULN - AST = 5 times ULN - Urine protein:creatinine ratio = 1.0 at screening - Patients with other prior malignancies are eligible, provided they have been treated with curative intent and have no evidence of recurrence - Not pregnant or nursing - Negative pregnancy test - No contraindications to MRI, including any of the following: - Hypersensitivity to gadolinium - Metallic device, including pacemaker, non-MRI compatible aneurysm clip, other non-MRI-compatible mechanical and/or electrical device, or metallic fragments - Severe claustrophobia Additional criteria for patients receiving bevacizumab: - No significant traumatic injury within the past 28 days - No serious nonhealing wounds, ulcers, or bone fractures - No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months - No myocardial infarction, unstable angina, or cerebrovascular accident within the past 6 months - No clinically significant peripheral vascular disease - No New York Heart Association class II-IV congestive heart failure - Patients with pre-existing hypertension should be on a stable antihypertensive regimen with blood pressure = 150/100 mm Hg at study entry PRIOR CONCURRENT THERAPY: Criteria for all patients - Prior adjuvant treatment including oxaliplatin allowed - No prior bevacizumab - At least 14 days since prior radiotherapy and recovered - More than 6 months since prior chemotherapy - No other concurrent investigational agents Additional criteria for patients receiving bevacizumab: - At least 28 days since prior major surgical procedure or open biopsy - At least 7 days since prior minor surgical procedure (e.g., fine-needle aspirations or core biopsies) - No anticipation of need for a major surgical procedure during study treatment - Concurrent oral or parenteral anticoagulation therapy allowed provided dose is stable |
Country | Name | City | State |
---|---|---|---|
United States | Abramson Cancer Center of the University of Pennsylvania | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Abramson Cancer Center of the University of Pennsylvania | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Analysis of tumor blood flow, assessed by DCE-MRI as percentage change in Ktrans, after 2 courses of FOLFOX and bevacizumab or FOLFOX alone compared to baseline value | 2 cycles for all subjects | ||
Secondary | Analysis of tumor markers of angiogenesis and apoptosis, and the effect of treatment | 2 cycles for all subjects | ||
Secondary | Correlation of tumor blood flow with time to progression | 2 cycles | ||
Secondary | Correlation of markers of apoptosis in tumor cells with response to therapy, time to progression, and overall survival | 2 cycles for all subjects |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |